Immunosenescence-Driven Hemodynamic Dysregulation and Cognitive Impairment in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Integrative Perspective.
Xu, Huimin, Luo, Yingzhe, Wu, Xi · Comprehensive Physiology · 2026 · DOI
Quick Summary
This review examines how ME/CFS may involve aging of the immune system that affects blood flow to the brain, causing cognitive problems like 'brain fog.' The researchers propose that this immune aging triggers chronic inflammation, reduces oxygen delivery to brain cells, and damages the protective barrier around the brain, leading to memory and thinking difficulties. The authors suggest that treatments targeting inflammation, improving blood vessel function, and modulating immune responses could help improve cognition in ME/CFS patients.
Why It Matters
Understanding the mechanistic link between immune aging, vascular dysfunction, and cognitive impairment could explain why ME/CFS patients experience persistent brain fog and opens new therapeutic avenues beyond symptomatic treatment. This integrative framework may help clinicians recognize cognition changes as part of systemic dysregulation rather than purely neuropsychiatric, potentially improving diagnostic and treatment approaches. For researchers, the proposed immune-vascular-cognitive axis provides a testable hypothesis that connects multiple observed ME/CFS pathologies into a unified biological mechanism.
Observed Findings
Immunosenescence and inflammaging are associated with altered T-, NK-, and B-cell function and elevated senescence-associated secretory phenotype (SASP) factors
Chronic low-grade inflammation is proposed to impair cerebral blood flow regulation and endothelial nitric oxide production
Brain hypoperfusion and oxidative stress are associated with impaired neuronal energy metabolism and reduced synaptic plasticity in memory-related brain networks
Multiple therapeutic approaches (cytokine blockade, nitric oxide enhancement, immune modulation, acupuncture) are proposed as potential interventions for neurovascular impairment
Inferred Conclusions
Immunosenescence-driven inflammaging creates a pathological state that compromises both vascular and neuronal function in ME/CFS
The combination of immune aging, vascular dysfunction, and neurometabolic impairment forms an integrated mechanism explaining persistent cognitive symptoms
Targeted therapies addressing the immune-vascular-cognitive axis may offer new treatment strategies for brain fog and cognitive decline in ME/CFS
Remaining Questions
What specific immune markers and senescence signatures are elevated in ME/CFS patients versus healthy controls and age-matched comparisons?
How do cerebral blood flow patterns in ME/CFS correlate with immune parameters and cognitive performance in prospective studies?
What This Study Does Not Prove
This is a mechanistic review and does not present original experimental evidence or clinical trial data proving that immunosenescence causes cognitive symptoms in ME/CFS patients. The proposed mechanisms are largely inferred from literature synthesis and have not yet been directly validated in ME/CFS cohorts with simultaneous measurement of immune markers, cerebral blood flow, and cognitive outcomes. The study does not establish causation or demonstrate that targeting these pathways will effectively restore cognition in clinical populations.
Which proposed therapeutic interventions (cytokine blockade, NO enhancement, immune modulation, acupuncture) demonstrate efficacy in clinical trials for improving cognition in ME/CFS?
Does immunosenescence severity predict cognitive decline severity or treatment response in ME/CFS, and can immune age be reliably reversed?